Seer Inc Ordinary Shares - Class A SEER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SEER is a good fit for your portfolio.
News
-
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
-
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
-
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
-
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
-
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Trading Information
- Previous Close Price
- $1.76
- Day Range
- $1.79–1.92
- 52-Week Range
- $1.46–5.56
- Bid/Ask
- $1.92 / $1.93
- Market Cap
- $123.72 Mil
- Volume/Avg
- 566,696 / 514,101
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.01%
Company Profile
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 147
- Website
- https://www.seer.bio
Comparables
Valuation
|
Metric
|
SEER
|
NAUT
|
VSBC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 3,629.76 |
Price/Book Value | 0.29 | 1.11 | 1,908.62 |
Price/Sales | 7.44 | — | 664.53 |
Price/Cash Flow | — | — | 2,904.34 |
Price/Earnings
SEER
NAUT
VSBC
Financial Strength
|
Metric
|
SEER
|
NAUT
|
VSBC
|
|---|---|---|---|
Quick Ratio | 24.42 | 19.01 | 4.32 |
Current Ratio | 25.00 | 19.39 | 4.33 |
Interest Coverage | — | — | — |
Quick Ratio
SEER
NAUT
VSBC
Profitability
|
Metric
|
SEER
|
NAUT
|
VSBC
|
|---|---|---|---|
Return on Assets (Normalized) | −11.17% | −15.61% | 42.38% |
Return on Equity (Normalized) | −12.25% | −17.76% | 65.38% |
Return on Invested Capital (Normalized) | −15.40% | −19.72% | 55.23% |
Return on Assets
SEER
NAUT
VSBC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mylppsljx | Flx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hbqnqspp | Smcbbj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Htmjwkh | Whgjw | $97.8 Bil | |
MRNA
| Moderna Inc | Fvxpqpspl | Sysl | $38.8 Bil | |
ARGX
| argenx SE ADR | Sjstzlznl | Hqkbl | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Cwypxbsc | Lyf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xnrpydw | Mmykvl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bhvqlvcbv | Zcxjdp | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qmbdybwrc | Xlzxclw | $12.5 Bil | |
INCY
| Incyte Corp | Knvxsmjd | Vmvvndr | $11.5 Bil |